Ozempic is FDA-approved for adults with type 2 diabetes, and that diagnosis is the primary qualification. It is not approved for weight loss on its own, though some doctors prescribe it off-label for that purpose. Whether you actually get a prescription depends on your diagnosis, your medical history, and what your insurance plan requires.
The Three FDA-Approved Uses
Ozempic (semaglutide) has three official indications, all tied to type 2 diabetes:
- Blood sugar management: As an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Cardiovascular protection: To reduce the risk of heart attack, stroke, and cardiovascular death in adults who have both type 2 diabetes and established heart disease.
- Kidney protection: To slow kidney decline and reduce the risk of kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
There is no specific A1c number or blood sugar threshold written into the FDA label. If you have a type 2 diabetes diagnosis, you technically qualify from a regulatory standpoint. In practice, though, your doctor will consider how well your current treatment is working and whether adding Ozempic makes sense for your situation.
What About Weight Loss Without Diabetes?
Ozempic is not FDA-approved for weight loss. The drug approved specifically for weight management is Wegovy, which contains the same active ingredient (semaglutide) at a higher dose. Wegovy is approved for adults and children 12 and older with obesity, as well as for cardiovascular risk reduction in adults with heart disease who are overweight or obese.
Some doctors do prescribe Ozempic off-label for weight loss. When they do, the typical thresholds mirror obesity treatment guidelines: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, or sleep apnea. But off-label use comes with a significant catch: most insurance plans won’t cover it.
Who Cannot Take Ozempic
Two groups of people are explicitly ruled out. You should not use Ozempic if you have a personal or family history of medullary thyroid carcinoma, a rare type of thyroid cancer. The same applies if you have a condition called Multiple Endocrine Neoplasia syndrome type 2, a genetic disorder that raises the risk of certain tumors. You’re also disqualified if you’ve had a serious allergic reaction to semaglutide or any ingredient in the injection.
Ozempic is approved only for adults. There is no pediatric approval for this specific brand, though Wegovy does have approval for patients as young as 12.
What Insurance Companies Require
Having a qualifying diagnosis doesn’t guarantee coverage. Most insurance plans require prior authorization before they’ll pay for Ozempic, and the requirements can be strict. A representative example comes from Florida Blue, one of the largest commercial insurers: their plans cover GLP-1 drugs only for type 2 diabetes, require clinical documentation of the diagnosis, and will deny any request for off-label use including weight loss.
Many insurers also enforce step therapy, meaning you need to show that less expensive medications didn’t work well enough before they’ll approve Ozempic. The most common requirement is that you’ve tried and had inadequate results with metformin, metformin combination drugs, or insulin. Your doctor will need to submit documentation showing this. If you haven’t tried those first-line options, your authorization request will likely be denied.
Combining metformin with Ozempic is actually a common treatment approach. Many people start on metformin alone, and when blood sugar stays above target, adding Ozempic helps lower A1c further. So step therapy isn’t just an insurance hurdle; it reflects how diabetes treatment typically progresses in real clinical practice.
Ozempic vs. Wegovy: Which One Fits?
Since both drugs contain semaglutide, the distinction comes down to what you’re being treated for. Ozempic is a diabetes medication. Wegovy is a weight management and cardiovascular risk medication. If you have type 2 diabetes, Ozempic is the standard path and the one insurance is most likely to cover. If your primary concern is weight loss and you don’t have diabetes, Wegovy is the appropriate option, though its insurance coverage varies widely and many plans exclude it entirely.
Wegovy also has a broader approval for cardiovascular risk reduction that doesn’t require a diabetes diagnosis, only obesity or overweight combined with heart disease. Ozempic’s cardiovascular indication, by contrast, specifically requires type 2 diabetes alongside established heart disease.
How the Qualification Process Works in Practice
Your doctor will start with your diagnosis. If you have type 2 diabetes, they’ll look at your current A1c, what medications you’ve already tried, and whether you have additional conditions like heart disease or kidney disease that might make Ozempic especially beneficial. They’ll then submit a prior authorization to your insurance, including lab results and your medication history.
If you’re seeking Ozempic for weight loss without a diabetes diagnosis, the path is harder. Your doctor may prescribe it off-label, but you’ll likely pay out of pocket, and the cost without insurance runs roughly $900 to $1,000 per month. Some telehealth services and cash-pay pharmacies offer alternatives, but coverage through traditional insurance for off-label weight loss use remains rare.
The approval timeline varies. Some prior authorizations come back within 24 to 72 hours. Others involve appeals if your first request is denied, which can take weeks. Having thorough documentation from your doctor, especially proof that first-line treatments were insufficient, speeds up the process significantly.